PEGylated antibodies and antibody fragments for improved therapy: a review (Q34674773)

3 August 2017

1 reference

title

PEGylated antibodies and antibody fragments for improved therapy: a review (English)

1 reference

3 August 2017

1 reference

Andrew P Chapman

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

Advanced Drug Delivery Reviews

3 August 2017

published in

1 reference

3 August 2017

volume

54

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

531-545

1 reference

Biopharmaceutical benchmarks

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Human antibodies by design

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Functionalized Poly(ethylene glycols) for Preparation of Biologically Relevant Conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Use of poly(ethylene glycol)-modified antibody in cell extraction

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Bioextraction of low abundance cells by affinity partitioning

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Biological activities of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

LABORATORY SYNTHESIS OF POLYETHYLENE GLYCOL DERIVATIVES

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

PEG thiazolidine-2-thione, a novel reagent for facile protein modification: conjugation of bovine hemoglobin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Preparation of characterization of poly(ethylene glycol) vinyl sulfone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Physicochemical and biological properties of poly(ethylene glycol)-coupled immunoglobulin G

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Comparative pharmacokinetic properties of murine monoclonal antibody A7 modified with neocarzinostatin, dextran and polyethylene glycol.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Therapeutic antibody fragments with prolonged in vivo half-lives

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Polymer modification of antibody to eliminate immune complex and Fc binding

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

The binding site for C1q on IgG

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Localization of the binding site for the human high-affinity Fc receptor on IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Tolerogenic polyethylene glycol derivatives of xenogeneic monoclonal immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900026-1

7 January 2021

10.1016/S0169-409X(02)00026-1

Identifiers

DOI

1 reference

3 August 2017

1 reference